<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier		N/A
name, catalogue number and RRID, if available.		Not use

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	NCL-H358 cells (RRID: CVCL_1559)	
Provide accession number in repository OR	NCL-H69 cells (RRID: CVCL_1579)	
supplier name, catalog number, clone number,	Methods/paragraph 3	
OR RRID		
Primary cultures: Provide species, strain, sex of		N/A
origin, genetic modification status.		Not use

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		N/A
genetic modification status. Provide accession		Not use
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		N/A
field: Provide species, sex and age where		Not use
possible		
Model organisms: Provide Accession number		N/A
in repository (where relevant) OR RRID		Not use

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession		N/A
number if available, and source (including location for collected wild specimens)		Not use
Microbes: provide species and strain, unique		N/A
accession number if available, and source		Not use

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	Research Ethics Committee (IS2118) of Shanghai	
equivalent committee(s), provide reference number	Chest Hospital	
for approval.	Methods/paragraph 1	
Provide statement confirming informed consent	Informed consent was obtained from all participants	
obtained from study participants.	Methods/paragraph 1	
Report on age and sex for all study participants.	2 male, one 56 year old, one 58 year old	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration		N/A
number OR cite DOI in manuscript.		
Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		N/A
by-step protocols are available.		
Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been		
done, or if they were not carried out.		
Sample size determination	2 cases	
Randomisation		N/A
Blinding		N/A
Inclusion/exclusion criteria		N/A
Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was	3	
replicated in laboratory	Methods/Paragraph 7	
Define whether data describe technical or biological		N/A
replicates		
Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	Research Ethics Committee (IS2118) of Shanghai Chest	
authority granting ethics approval (IRB or equivalent	Hospital	
committee(s), provide reference number for	Methods/paragraph 1	
approval.		
Studies involving experimental animals: State details		N/A
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if		N/A
relevant permits obtained, provide details of		
authority approving study; if none were required,		
explain why.		
Dual Use Research of Concern (DURC)	Vos (indicato whore provided; section/paragraph)	n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,		N/A
state the authority granting approval and reference		
number for the regulatory approval		

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		N/A
excluded, and whether the criteria for exclusion were		1
determined and specified in advance.		1

Statistics	Yes (indicate where provided: section/paragraph)	n/a	
Describe statistical tests used and justify choice of	A two-tailed Student t-test was performed to calculate		
tests.	the statistically significant differences between two		
	groups. A P value < 0.05 was considered statistically		
	significant. (Methods/Paragraph 8)		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	Statistical analysis plan, informed consent form, raw	
including protocols for access or restriction on	data of sequencing and clinical study report will be	
access.	shared if requested	
If data are publicly available, provide accession		N/A
number in repository or DOI or URL.		
If publicly available data are reused, provide		N/A
accession number in repository or DOI or URL, where		
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential		
for replicating the main findings of the study:		
State whether the code or software is available.		N/A
If code is publicly available, provide accession number in repository, or DOI or URL.		N/A

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/atm-21-2625